Boston Pharmaceuticals products

BOS-981 is a first-in-class, small molecule furin inhibitor with therapeutic potential in pulmonary diseases, including cystic fibrosis (CF), vascular diseases, and infectious diseases.

BOS-580 has the potential to reduce hepatic fat and fibrosis. BOS-580 is an injectable, genetically engineered variant of human fibroblast growth factor 21 (FGF21).

BOS-467 has the potential to reduce hepatic fat and fibrosis. BOS-467 is a humanized β-klotho agonist monoclonal antibody that mimics FGF21 biology.

BOS-857 is a first-in-class, inhaled, small molecule furin inhibitor with therapeutic potential in pulmonary diseases, including cystic fibrosis (CF), vascular diseases, and infectious diseases.